---
title: "BUCHANG PHARMA released its semi-annual performance, with a net profit attributable to the parent company of 628 million yuan, a year-on-year increase of 171.24%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/254753375.md"
description: "According to the Zhitong Finance APP, BUCHANG PHARMA disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 5.664 billion yuan, a year-on-year increase of 4.27%; net profit attributable to the parent company was 628 million yuan, a year-on-year increase of 171.24%; net profit excluding non-recurring gains and losses was 619 million yuan, a year-on-year increase of 180.04%; basic earnings per share were 0.5934 yuan. The company plans to distribute a cash dividend of 3.90 yuan (tax included) for every 10 shares"
datetime: "2025-08-27T07:46:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254753375.md)
  - [en](https://longbridge.com/en/news/254753375.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254753375.md)
generator: "portal-rs"
---

# BUCHANG PHARMA released its semi-annual performance, with a net profit attributable to the parent company of 628 million yuan, a year-on-year increase of 171.24%

According to the Zhitong Finance APP, BUCHANG PHARMA (603858.SH) disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 5.664 billion yuan, a year-on-year increase of 4.27%; net profit attributable to shareholders was 628 million yuan, a year-on-year increase of 171.24%; net profit excluding non-recurring items was 619 million yuan, a year-on-year increase of 180.04%; basic earnings per share were 0.5934 yuan. The company plans to distribute a cash dividend of 3.90 yuan (tax included) for every 10 shares

### Related Stocks

- [603858.CN](https://longbridge.com/en/quote/603858.CN.md)

## Related News & Research

- [TrueBlue PeopleScout report shows 52% of job seekers use AI in job search, communication gaps persist](https://longbridge.com/en/news/296352258.md)
- [DIMRI: H1 2026 net profit rose to ₪495.6M on revenue of ₪780.5M, with robust liquidity and equity](https://longbridge.com/en/news/296448412.md)
- [Rapala VMC: Strong H1 sales and profit growth led to upgraded full-year outlook amid ongoing trade risks](https://longbridge.com/en/news/296480810.md)
- [Hengrui Pharma launches RMB 1 billion-RMB 2 billion A-share buyback, caps price at RMB 81.78](https://longbridge.com/en/news/296368941.md)
- [Shurgard announces availability of FY2025 full-year results report](https://longbridge.com/en/news/296451547.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**